Publication 3ème trim 2024

Bonjour à tous,
Vous trouverez ci-dessous les titres des publications des membres du réseau ENDOCAN TUTHYREF.
Félicitations aux auteurs!

Retrouvez les publications dans :   Espace membre

3ème trim 2024

Requête:

(RAHIM A[Author] OR ALGHUZLAN A[Author] OR BARDET S[Author] OR BARGE ML[Author] OR BATISSE-LIGNIER M[Author] OR BENISVY D[Author] OR BORSON-CHAZOT F[Author] OR Calcagno F[Author] OR BUFFET C[Author] OR Lussey-Lepoutre C[Author] OR Chevalier B[Author] OR CHOUGNET C[Author] OR Sajous C[Author] OR CIAPPUCCINI R[Author] OR Cogne M[Author] OR CRINIERE L[Author] OR CUNY T[Author] OR De la Fouchardière C[Author] OR DESAILLOUD R[Author] OR DO CAO C[Author] OR DRUI D[Author] OR DRUTEL A[Author] OR DYGAI-COCHET I[Author] OR EDET-SANSON A[Author] OR Gilly O[Author] OR GODBERT Y[Author] OR GROUSSIN L[Author] OR GRUNENWALD S[Author] OR Lasolle H[Author] OR HESCOT S[Author] OR ILLOUZ F[Author] OR Borget I[Author] OR JANNIN A[Author] OR KARABAJAKIAN A[Author] OR KELLY A[Author] OR LABOUREAU S[Author] OR LAMBERT A[Author] OR LAMARTINA L[Author] OR Haissaguerre M[Author] OR MULLER M[Author] OR NARCISO B[Author] OR Pinochet P[Author] OR Raymond P[Author] OR RODIEN P[Author] OR ROUDAUT N[Author] OR SALAS S[Author] OR SCHNEEGANS O[Author] OR SCHVARTZ C[Author] OR Castellnou S[Author] OR VELAYOUDOM-CEPHISE FL[Author] OR VERA P[Author] OR ZALZALI M[Author] OR ZANETTA S[Author] OR ZERDOUD S[Author] OR HADOUX J[Author] OR Nascimento C[Author] OR Eberle MC[Author] OR CATARGI B[Author] OR CHABRE O[Author] OR KLEIN M[Author] OR LEENHARDT L[Author] OR NICOLLI P[Author] OR TAIEB D[Author] OR RUSU D[Author] OR Schlumberger M[Author] OR Leboulleux S[Author] OR TUTHYREF OR ENDOCAN-RENATEN) AND ("thyroid neoplasms"[Mesh] OR (("Thyroid"[tw] OR "Thyroid Gland"[Mesh]) AND ("Neoplasms"[Mesh] OR "neoplas*"[tw] OR "tumor*"[tw] OR "tumour*"[tw] OR "cancer*"[tw] OR "lymphoma*"[tw] OR "malignan*"[tw] OR "oncolog*"[tw] OR "carcinom*"[tw] OR "adenoma*"[tw] OR "TUTHYREF" OR "ENDOCAN-RENATEN"))) AND ((2024/06/30[edat]: 2024/10/01[edat]) OR (2024/06/30[epdat]: 2024/10/01[epdat]) OR (2024/06/30[dp]: 2024/10/01[dp]))

Résultat :

  1. Attia A, Touma E, Lussey-Lepoutre C, Ghander C, Jouinot A, Roy M, Housni S, Chereau N, Menegaux F, Leenhardt L, Buffet C. Consideration of Early Dynamic Risk Stratification to Guide Discharge from Oncologic Follow-up in Patients with Differentiated Thyroid Cancer. Thyroid. 2024 Sep 17. doi: 10.1089/thy.2024.0119. Epub ahead of print. PMID: 39287064.

  2. Donzé C, Leenhardt F, Vinches M, Eberlé MC, Fersing C. Clinical Pharmacy Initiatives Contribute to the Excellent Efficacy of the Dabrafenib/Trametinib Combination for Iodine-Refractory Thyroid Carcinoma: A Case Report. Medicina (Kaunas). 2024 Jun 25;60(7):1037. doi: 10.3390/medicina60071037. PMID: 39064466; PMCID: PMC11278742.

  3. Leboulleux S, Kapiteijn E, Litière S, Schöffski P, Godbert Y, Rodien P, Jarzab B, Salvatore D, Zanetta S, Capdevila J, Bastholt L, De La Fouchardiere C, Lalami Y, Bardet S, Cornélis F, Dedecjus M, Links T, Sents W, Schlumberger M, Locati DL, Newbold K. Safety and efficacy of nintedanib as second-line therapy for patients with differentiated or medullary thyroid cancer progressing after first-line therapy. A randomized phase II study of the EORTC Endocrine Task Force (protocol 1209-EnTF). Front Endocrinol (Lausanne). 2024 Jun 27;15:1403687. doi: 10.3389/fendo.2024.1403687. PMID: 39015176; PMCID: PMC11250516.

  4. Rao KN, Randolph GW, Lopez F, Zafereo M, Coca-Pelaz A, Piazza C, Dange P, Rodrigo JP, Stenman G, de Keizer B, Nixon I, Sinha S, Leboulleux S, Mäkitie AA, Agaimy A, Thompson L, Ferlito A; This paper was written by members and invitees of the International Head and Neck Scientific Group. Assessment of the risk of malignancy in Bethesda III thyroid nodules: a comprehensive review. Endocrine. 2024 Aug;85(2):473-492. doi: 10.1007/s12020-024-03737-z. Epub 2024 Feb 28. PMID: 38416380.

  5. Wirth LJ, Brose MS, Subbiah V, Worden F, Solomon B, Robinson B, Hadoux J, Tomasini P, Weiler D, Deschler-Baier B, Tan DSW, Maeda P, Lin Y, Singh R, Bayt T, Drilon A, Cassier PA. Durability of Response With Selpercatinib in Patients With RET-Activated Thyroid Cancer: Long-Term Safety and Efficacy From LIBRETTO-001. J Clin Oncol. 2024 Sep 20;42(27):3187-3195. doi: 10.1200/JCO.23.02503. Epub 2024 Aug 2. PMID: 39094065; PMCID: PMC11404750.